Scilex Holding Company (SCLX) has provided an announcement.
Scilex Holding Company is considering a strategic move to boost the value of its subsidiary, Semnur Pharmaceuticals, and its product candidate, SEMDEXA™. The Board of Directors has given the green light to investigate various options, such as a spin-off, merger, or other transactions, with the goal of enhancing stockholder returns. This initiative represents a proactive approach to capitalize on the subsidiary’s assets and potential.
See more insights into SCLX stock on TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
